OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for OPKO Health in a research note issued on Monday, April 7th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will earn ($0.07) per share for the quarter, up from their previous estimate of ($0.08). HC Wainwright currently has a "Buy" rating and a $3.00 target price on the stock. The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health's FY2025 earnings at ($0.29) EPS.
Several other research analysts have also recently issued reports on the company. Barrington Research restated an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Wednesday, March 12th. StockNews.com upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday, March 3rd.
Check Out Our Latest Stock Report on OPKO Health
OPKO Health Stock Up 0.4 %
NASDAQ OPK traded up $0.01 during trading on Thursday, hitting $1.42. The company's stock had a trading volume of 2,327,629 shares, compared to its average volume of 3,944,092. OPKO Health has a fifty-two week low of $1.15 and a fifty-two week high of $2.04. The company has a market cap of $953.60 million, a PE ratio of -7.47 and a beta of 1.78. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The business's 50 day simple moving average is $1.69 and its 200-day simple moving average is $1.58.
OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The company had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%.
Insider Activity
In related news, CEO Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock in a transaction that occurred on Wednesday, January 15th. The shares were purchased at an average cost of $1.48 per share, for a total transaction of $740,000.00. Following the acquisition, the chief executive officer now owns 213,036,477 shares in the company, valued at approximately $315,293,985.96. This represents a 0.24 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last quarter, insiders have bought 1,464,971 shares of company stock valued at $2,268,692. 49.69% of the stock is currently owned by insiders.
Hedge Funds Weigh In On OPKO Health
Several hedge funds have recently bought and sold shares of OPK. Millennium Management LLC grew its position in shares of OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock valued at $6,745,000 after buying an additional 2,112,382 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in shares of OPKO Health by 143.6% in the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company's stock valued at $3,746,000 after purchasing an additional 1,502,342 shares during the last quarter. Altshuler Shaham Ltd purchased a new position in OPKO Health during the 4th quarter worth approximately $2,082,000. Norges Bank purchased a new position in shares of OPKO Health during the fourth quarter worth approximately $1,657,000. Finally, Two Sigma Investments LP increased its holdings in shares of OPKO Health by 136.1% in the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock valued at $2,422,000 after acquiring an additional 949,671 shares during the period. Institutional investors and hedge funds own 64.63% of the company's stock.
OPKO Health Company Profile
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Further Reading
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
